Abstract:
Amitriptyline, an agent universally used to treat depression, has an anti-inflammatory activity and a potential
for lowering inflammatory mediators. Periodontal diseases like gingivitis and periodontitis if untreated contributes to
gingival tissue destruction and bone resorption. These diseases are commonly treated with conventional non-steroidal
anti-inflammatory agents and antibiotics along with standard periodontal treatment. The aim of this experimental,
observational and randomized clinical control trial was to evaluate the anti-inflammatory effects of amitriptyline on
clinical parameters and on inflammatory biomarkers in patients of periodontal diseases by developing 1% oral gel and
mouthwash formulations. 30 patients participated in the study were grouped in three categories, patients received
standard conventional treatment, patients received gel treatment for four weeks after standard treatment, patients
received mouthwash for four weeks after standard periodontal treatment. Results showed that amitriptyline gel and
mouthwash in 1% formulation showed promising results by significantly reducing periodontal parameters and
inflammatory biomarkers (p≤0.001) as compared to standard treatment. Thus, we suggest that gel and mouthwash
formulation of amitriptyline is highly efficacious in treating the periodontal diseases.
